Galapagos business update
(Thomson Reuters ONE) -
Mechelen, Belgium; 10 November 2011 - Galapagos NV (Euronext: GLPG) announces
today that third quarter 2011 operational and financial results were in line
with management expectations. Management believes the 2011 financial guidance
given earlier this year to be achievable conditional upon reaching certain R&D
revenues: group revenues of over ?146 million, with positive operational income
and cash flow, and a positive net result in 2011.
New alliance in oncology
In September Galapagos signed a new strategic alliance with leading French
pharma Servier to develop new therapies in oncology. Under the terms of the
agreement, Galapagos received a research access payment of ?2 million from
Servier and is eligible to receive milestone payments of up to ?260 million,
plus royalties upon commercialization of products. For any marketed products,
Galapagos also retains exclusive U.S. commercialization rights. The total,
risk-adjusted value of Galapagos' alliance programs is now ?2.8 billion plus
royalties, and US commercial rights on the Servier alliances.
Deals for service operations
BioFocus initiated a Parkinson's disease diagnostic collaboration with the
Michael J. Fox Foundation and further capitalized on the synergies between
Argenta and BioFocus through a two-year deal extension with Genentech, worth up
to ?23 million.
Clinical progress
In July Galapagos initiated a Proof-of-Mechanism clinical study for candidate
cachexia drug GLPG0492. Furthermore, Galapagos completed recruitment for a
Phase II clinical study for GLPG0634, a Janus kinase 1 (JAK1) inhibitor being
developed for inflammatory conditions such as rheumatoid arthritis (RA), and is
on-track to deliver topline results on 22 November 2011. The clinical Proof-of-
Mechanism study for GLPG0778 was also completed.
Outlook
Management believes the full-year 2011 guidance figures achievable yet
conditional upon reaching certain R&D revenues: Group revenues of ?146 million,
a positive operational result and cash flow and a positive net result. The
Company expects to report Phase II efficacy data from GLPG0634 on 22 November
2011. Galapagos also will report results from the GLPG0778 Phase I Proof-of-
Mechanism study and complete the Phase I Proof-of-Mechanism study with GLPG0492
before year end. Galapagos further aims to deliver multiple alliance milestones
and outlicense one internal program before end 2011.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with seven programs in development and over 50
discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline,
Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to
receive up to ?2.8 billion in downstream milestones, plus royalties. The
Galapagos Group has about 800 employees and operates facilities in six
countries, with global headquarters in Mechelen, Belgium. More info at:
www.glpg.com
CONTACT
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1562506]
Unternehmensinformation / Kurzprofil:
Datum: 10.11.2011 - 07:31 Uhr
Sprache: Deutsch
News-ID 86225
Anzahl Zeichen: 5646
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos business update"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
